Summary

DelveInsight’s, LAG-3 AntagonistPipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The LAG-3 Antagonist Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, LAG-3 Antagonist-Pipeline Insights, 2015 Report covers the LAG-3 Antagonist pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonist related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonist.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the Mechanism of Action (MoA).

Scope

• DelveInsight’s report provides a LAG-3 Antagonist Landscape across the globe
• The report provides drug profiles which includes product description, licensors & collaborators, development partner and chemical information
• Coverage of the LAG-3 Antagonist pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for LAG-3 Antagonist and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

• Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonist.
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Track your competitors and develop strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
• Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of Contents

LAG-3 Antagonist Overview
LAG-3 Antagonist Disease Associated
LAG-3 Antagonist Pipeline Therapeutics
LAG-3 Antagonist Therapeutics under Development by Companies
LAG-3 Antagonist Late Stage Products (Filed and Phase III)
Comparative Analysis
LAG-3 Antagonist Mid Clinical Stage Products (Phase II)
Comparative Analysis
LAG-3 Antagonist  Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
LAG-3 Antagonist Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
LAG-3 Antagonist– Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
LAG-3 Antagonist– Discontinued Products
LAG-3 Antagonist – Dormant Products
Companies Involved in Therapeutics Development for LAG-3 Antagonist
Appendix
Methodology
Contact Us
Disclaimer

List of Tables

Number of Products under Development for LAG-3 Antagonist by Therapy Area, 2015
Number of Products under Development for LAG-3 Antagonist,2015
Number of Products under Development by Companies
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
Drug Candidates Profiles
LAG-3 Antagonist Assessment by Monotherapy Products
LAG-3 Antagonist Assessment by Combination Products
LAG-3 Antagonist Assessment by Route of Administration
LAG-3 Antagonist Assessment by Stage and Route of Administration
LAG-3 AntagonistAssessment by Molecule Type
LAG-3 Antagonist Assessment by Stage and Molecule Type
LAG-3 Antagonist Therapeutics – Discontinued Products
LAG-3 Antagonist Therapeutics – Dormant Products
Products under Development by Companies, 2015

List of Figures

Number of Products under Development for LAG-3 Antagonist by Therapy Area, 2015
Number of Products under Development for LAG-3 Antagonist, 2015
Late Clinical Stage Products (Filed and Phase III), 2015
Mid Clinical Stage Products (Phase II), 2015
Early Clinical Stage Products (Phase I and IND Filed), 2015
Discovery and Pre-Clinical Stage Products, 2015
LAG-3 Antagonist Assessment by Monotherapy Products
LAG-3 Antagonist, Assessment by Combination Products
LAG-3 Antagonist, Assessment by Route of Administration
LAG-3 Antagonist, Assessment by Stage and Route of Administration
LAG-3 Antagonist, Assessment by Molecule Type
LAG-3 Antagonist, Assessment by Stage and Molecule Type